ArticleAnnals of hematology2023

Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study.

Ilseung Choi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.